Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer.

Linjun HuQinxin ZhaoHongsong BaiChengming XieXingli ShanDehu LuYonghai ChenDongdong HanZejun XiaoJun TianDong WangXingang BiNian-Zeng Xing

Published in: Cancer management and research (2020)

ADT combined with 6 cycles of docetaxel + prednisone chemotherapy benefits patients diagnosed with high-burden mHSPC in terms of the OS, PFS of PSA and radiographic, and the ratio of PSA falling to 0.2 ng/mL.

Keyphrases

prostate cancer
radical prostatectomy
end stage renal disease
locally advanced
ejection fraction
squamous cell carcinoma
newly diagnosed
chronic kidney disease
peritoneal dialysis
risk factors
prognostic factors
stem cells
patient reported outcomes
rectal cancer
smoking cessation